転移 し た 乳がん の 治療 の ため の 免疫 療法 の 最近 の 進歩
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。乳がん (BC),特に転移性三重陰性BC (TNBC) に対してPD- 1/ PD- L1阻害剤を用いた免疫療法は有望である. 組み合わせ戦略とバイオマーカーは 耐性を克服し 患者の生存率を向上させるための鍵です
科学分野
- 腫瘍学
- 免疫学
- 医学 研究
背景
- 乳がん (BC) は女性の主要な悪性腫瘍であり,腫瘍の異質性と耐性により治療が困難である.
- 免疫療法は,BCを含む様々な固体腫瘍に対する有望な治療法として,がんの発症における免疫系の役割のために出現しています.
- 可能性にもかかわらず,BC免疫療法は,低免疫性,T細胞浸透性低下,免疫抑制性腫瘍微環境 (TME) などの制限に直面しています.
研究 の 目的
- 乳がんの免疫療法における 最新の進歩をレビューする.
- 治療効果と患者の生存率を向上させるための新しい組み合わせ戦略とバイオマーカーを探求する.
- BC免疫療法の分野における課題と将来の方向性を議論する.
主な方法
- BC免疫療法に関する最近の臨床試験と研究のレビュー
- 転移性BC,特にトリプルネガティブBC (TNBC) のPD-1/PD- L1阻害剤の有効性の分析
- ワクチンや化学療法を含む結合免疫療法戦略の探索
主要な成果
- アテゾリズマブやペムブロリズマブのようなPD- 1/ PD- L1阻害剤は,転移性BC患者のサブセット,特にPD- L1陽性腫瘍,TNBC,または腫瘍浸透性リンパ球 (TILs) が多い患者の臨床効果を示しています.
- これらの阻害剤で治療された転移性TNBC患者で持続的な反応が観察されました.
- 研究は,抵抗を克服し,応答率を向上させるための組み合わせ戦略を積極的に追求しています.
結論
- 免疫療法,特にPD-1/PD-L1阻害は,特定の乳がんサブタイプに対する治療の可能性を提供します.
- 結合戦略とバイオマーカーの識別は,免疫療法の有効性と患者のアウトカムを改善するために不可欠です.
- 将来の研究は,乳がん患者の生存率を改善するための個別化された治療方法に焦点を当てるべきです.
関連する概念動画
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...